References
- Sánchez-Moya A, Dauden E. Incidence of tuberculosis infection in psoriatic patients on anti-TNF therapy: report of a case series with 144 patients. J Eur Acad Dermatol Venereol. 2011;25:730–3.
- Gisondi P, Pezzolo E, Lo Cascio G, Girolomoni G. Latent tuberculosis infection in patients with chronic plaque psoriasis who are candidates for biological therapy. Br J Dermatol. 2014;171:884–90.
- Kasiraman V, Atwan AA, Durojaiye OC, et al. Risk of tuberculosis with the use of anti-TNF medications in psoriasis: incidence, screening and management. Dermatol Online J. 2014;20:pii: 13030/qt8s09h73j.
- Solovan C, Chiticariu E. Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review. Infect Dis Ther. 2013;2:59–73.
- Shaikha SA, Mansour K, Riad H. Reactivation of tuberculosis in three cases of psoriasis after initiation of anti-TNF therapy. Case Rep Dermatol. 2012;4:41–6.
- Winthrop KL, Baxter R, Liu L, et al. Mycobacterial diseases and antitumour necrosis factor therapy in USA. Ann Rheum Dis. 2013;72:37–42.
- Gardam MA, Keystone EC, Menzies R, et al. Antitumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148–55.
- Paluch-Oleś J, Magryś A, Kozioł-Montewka M, et al. Identification of latent tuberculosis infection in rheumatic patients under consideration for treatment with anti-TNF-α agents. Arch Med Sci. 2013;9:112–17.
- Titton DC, Guimarães-Silveira I, Louzada-Junior P, et al. Brazilian Biologic Registry: biobada Brasil implementation process and preliminary results. Rev Bras Reumatol. 2011;51:145–60.
- Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am Thorac Soc MMWR Recomm Rep. 2000;49:1–51.
- Machado J, Moncada JC, Pineda R. Profile of use of anti-tumor necrosis factor in Colombian patients. Biomedica. 2011;31:250–7.
- Colombiás National Institute of Public Health. Analysis and surveillance of the public health risk. Public health surveillance protocol. Tuberculosis 2014. Available from http://www.vigepi.com.co/sivigila/pdf/protocolos/820p%20tbc.pdf. Accessed November 2014.
- World Health Organization. Tuberculosis Country Profiles 2014. Available from https://extranet.who.int/sree/Reports?op=Replet&name=%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=CO&LAN=EN&outtype=pdf. Accessed November 2014.
- Rojas-Villarraga A, Agudelo CA, Pineda-Tamayo R, et al. Tuberculosis in patients treated with tumor necrosis factor alpha antagonists living in an endemic area. Is the risk worthwhile? Biomedica. 2007;27:159–71.
- Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis. 2005;64:1360–1.
- Furst DE, Cush J, Kaufmann S, et al. Preliminary guidelines for diagnosing and treating tuberculosis in patients with rheumatoid arthritis in immunosuppressive trials or being treated with biological agents. Ann Rheum Dis. 2002;61:62–3.
- Hanta I, Ozbek S, Kuleci S, Kocabas A. The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients. Clin Rheumatol. 2008;27:1083–6.
- Yun JW, Lim SY, Suh GY, et al. Diagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea. J Korean Med Sci. 2007;22:779–83.
- Haroon M, Martin U, Devlin J. High incidence of intolerance to tuberculosis chemoprophylaxis. Rheumatol Int. 2012;32:33–7.
- Sichletidis L, Settas L, Spyratos D, et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis. 2006;10:1127–32.
- Cagatay T, Aydin M, Sunmez S, et al. Follow-up results of 702 patients receiving tumor necrosis factor-α antagonists and evaluation of risk of tuberculosis. Rheumatol Int. 2010;30:1459–63.